Intelligence · Clinical pipeline
Oncology · Phase III
Oncology programs at Phase III — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase III programs: NovaPharmaNews indexes 1,266 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- AstraZeneca 75 programs
- Chinese Academy of 70 programs
- HOFFMANN-LA ROCHE 68 programs
- MSD Merck Sharp 56 programs
- First People's Hospital 53 programs
- Ningbo Cancer Hospital 44 programs
- United Therapeutics Europe 43 programs
- Anaxis Pharma 37 programs
- AstraZeneca 37 programs
- Novartis India 32 programs
- George Institute for 29 programs
- Takeda 28 programs
Pipeline programs
-
5-Fluorouracil
Hoffmann-La Roche
Breast Cancer
1 trial -
5-Fluoruracil
Hoffmann-La Roche
Gastric Cancer
1 trial -
5-Fu/epirubicin/CTX following Docetaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
56021927PCR3001
Janssen-Cilag International N.V.
Metastatic castration-resistant prostate cancer (mCRPC)
1 trial -
56021927PCR3002
Janssen-Cilag International N.V.
Metastatic Hormone-sensitive Prostate Cancer
1 trial -
56021927PCR3015
Janssen-Cilag International N.V.
High risk recurrent prostate cancer previously treated with radical prostatectomy
1 trial -
6-Thio-2'-Deoxyguanosine
MAIA Biotechnology
Carcinoma, Non-Small-Cell Lung
2 trials -
6-month course of antiandrogen drugs
The First People's Hospital of Lianyungang
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1 trial -
61186372COR3001
Janssen-Cilag International N.V.
KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
1 trial -
61186372COR3002
Janssen-Cilag International N.V.
KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer
1 trial -
61186372HNC3001
Janssen-Cilag International N.V.
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
1 trial -
61186372NSC3001
Janssen-Cilag International N.V.
EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
61186372NSC3002
Janssen-Cilag International N.V.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
61186372NSC3004
Janssen-Cilag International N.V.
EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
1 trial -
64091742PCR3001
Janssen-Cilag International N.V.
Metastatic Prostate Cancer
1 trial -
64Cu(II)Cl2 solution for injection
A.C.O.M. - Advanced Center Oncology
Cancer on the prostatic bed
1 trial -
64Cu-PSMA I&T
Curium Romania S.R.L.
Prostate cancer
1 trial -
64Cu-PSMA I&T
Curium Romania S.R.L.
Prostate cancer
1 trial -
67652000PCR3002
Janssen-Cilag International N.V.
Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
1 trial -
68Ga-PSMA-11
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Biochemical Recurrence of Malignant Neoplasm of Prostate
1 trial -
73841937NSC3003
Janssen-Cilag International N.V.
EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer
1 trial -
7465-CL-0301
Astellas Pharma GmbH
Locally advanced or metastatic urothelial cancer
1 trial -
78278343PCR3001
Janssen-Cilag International N.V.
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1 trial -
78278343PCR3003
Janssen-Cilag International N.V.
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1 trial -
8951-CL-0301
Astellas Pharma GmbH
Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
1 trial -
8951-CL-0302
Astellas Pharma GmbH
Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
1 trial -
8951-CL-0305
Astellas Pharma GmbH
Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastric Adenocarcinoma
1 trial -
89Zr-CED88004S
Disc Medicine
Large B-cell lymphoma
1 trial -
89Zr-Girentuximab
Telix Innovations
Clear Cell Renal Cell Carcinoma
2 trials -
89Zr-TLX250 PET/CT
Telix Innovations
Clear Cell Renal Cell Carcinoma
1 trial -
91782
Bayer HealthCare AG
Breast Cancer
1 trial -
A021502
The George Institute
stage III colon adenocarcinoma with deficient MMR
1 trial -
ABC-HCC
The George Institute
intermediate-stage hepatocellular carcinoma
1 trial -
ABEMACICLIB , FULVESTRANT
Eli Lilly Co.
Breast cancer
1 trial -
ABP 206
Amgen
Melanoma
2 trials -
ABX-CT-302EU/EAGLE-i
Advanced Accelerator Applications
Prostate Cancer
1 trial -
AC220-168
Daiichi Sankyo
Acute myeloid leukemia
1 trial -
ACE-536-MF-002
Celgene Europe Limited
Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)
1 trial -
ACE-CL-007
Lacuna Pharma Pty Ltd
Chronic Lymphocytic Leukemia
1 trial -
ACE-CL-311 (AMPLIFY)
Lacuna Pharma Pty Ltd
Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
1 trial -
ACE-LY-308
Lacuna Pharma Pty Ltd
Mantle Cell Lymphoma
1 trial -
ADAURA - D5164C00001
AstraZeneca AB
Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy
1 trial -
ADSTILADRIN
Ferring Pharmaceuticals
Intermediate risk, non-muscle invasive bladder cancer
1 trial -
AFMMUChina
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
AG120-C-009
The George Institute
Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
1 trial -
AK112 Injection
Summit Therapeutics
Non-Squamous Non-small Cell Lung Cancer
1 trial -
ALKS 4230-007
Wuhan Createrna Science and Technology Co., Ltd
Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
1 trial -
ALL2820
Fondazione Telethon ETS
Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
1 trial
Frequently asked questions
How many oncology Phase III programs exist?
1,266 programs match both the therapeutic area and stage filters in our published index.